Compare NGG & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGG | GSK |
|---|---|---|
| Founded | 1990 | 1715 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7B | 96.1B |
| IPO Year | 1999 | N/A |
| Metric | NGG | GSK |
|---|---|---|
| Price | $88.07 | $57.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 759.5K | ★ 5.3M |
| Earning Date | 11-06-2025 | 02-04-2026 |
| Dividend Yield | ★ 3.58% | 3.14% |
| EPS Growth | 33.01 | ★ 123.15 |
| EPS | 0.78 | ★ 1.87 |
| Revenue | $23,499,206,920.00 | ★ $43,966,352,618.00 |
| Revenue This Year | N/A | $6.70 |
| Revenue Next Year | $11.63 | $5.10 |
| P/E Ratio | $110.06 | ★ $13.89 |
| Revenue Growth | N/A | ★ 4.12 |
| 52 Week Low | $59.35 | $32.38 |
| 52 Week High | $86.35 | $53.38 |
| Indicator | NGG | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 77.13 | 79.87 |
| Support Level | $84.30 | $49.60 |
| Resistance Level | $85.65 | $51.37 |
| Average True Range (ATR) | 1.20 | 0.81 |
| MACD | 0.50 | 0.64 |
| Stochastic Oscillator | 87.74 | 97.05 |
National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission and electricity generation in the United States, metering services, merchant transmission lines in the UK, and the Grain (UK) liquefied natural gas facility.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.